

Neeraj Mishra
Ashish Garg
Sumel Ashique *Editors*

Role of Gut Microbiota and Postbiotics for Colorectal Cancer

Advancing Therapeutic Strategies

 Humana Press

About this book

The emerging role of gut microbiota and postbiotics has implications for the management of not only human health and diseases, but also colorectal cancer in particular, as these elements influence colorectal cancer pathogenesis, treatment, and prevention. This book bridges the gap between cutting-edge research and practical clinical applications in the management of colorectal cancer by offering a fresh perspective on potential therapeutic strategies and exploring the significance of microbiota in the oncology landscape. Chapters delve into the specific impacts of postbiotics, linking them to immune response modulation, inflammation reduction, and direct anticancer effects. Chapters also explore current and emerging therapies, including the manipulation of gut microbiota and the use of postbiotics supplements. Clinical trial results, case studies, and expert opinions are interwoven to present a realistic view of the benefits, limitations, and future prospects of these innovative therapeutic strategies.

This book is rounded out with perspectives on future research directions in this area, discussing potential next-generation therapies such as personalized medicine approaches and biotechnological advancements, and further contemplating broader implications of microbiota research on public health strategies. Informative and engaging, this book provides clinicians and researchers alike with a deeper understanding of how postbiotics can be harnessed in colorectal cancer treatment and potentially, the treatment of other cancers influenced by gut health.

Neeraj Mishra • Ashish Garg • Sumel Ashique
Editors

Role of Gut Microbiota and Postbiotics for Colorectal Cancer

Advancing Therapeutic Strategies

 Humana Press

Editors

Neeraj Mishra
Amity Institute of Pharmacy
Amity University
Gwalior, Madhya Pradesh, India

Ashish Garg
Department of Pharmaceutics
Guru Ramdas Khalsa Institute of Science
and Technology (Pharmacy)
Jabalpur, Madhya Pradesh, India

Sumel Ashique
Department of Pharmaceutical Technology
Bharat Technology
Uluberia, West Bengal, India

ISSN 2196-9906 ISSN 2196-9914 (electronic)
Cancer Drug Discovery and Development
ISBN 978-3-031-86064-5 ISBN 978-3-031-86065-2 (eBook)
<https://doi.org/10.1007/978-3-031-86065-2>

© The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2025

This work is subject to copyright. All rights are solely and exclusively licensed by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, expressed or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This Humana imprint is published by the registered company Springer Nature Switzerland AG
The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland

If disposing of this product, please recycle the paper.

Preface

The “Role of Gut Microbiota and Postbiotics for Colorectal Cancer: Advancing Therapeutic Strategies” is a dynamically advancing domain at the convergence of microbiology, oncology, and precision medicine. This book examines the complex interrelationships among gut microbiota, postbiotic metabolites, and the development of colorectal cancer (CRC), illuminating the ways in which microbial dysbiosis, immunological regulation, and bioactive chemicals derived from microbes impact carcinogenesis and treatment results. As interest in microbiome-based therapies grows, a critical inquiry arises: Can postbiotics provide innovative approaches for the prevention and management of colorectal cancer?

This book connects fundamental microbiome science with translational and clinical applications through a multidisciplinary approach. The text commences with an extensive examination of gut microbiota composition, diversity, and function, highlighting their significance in the development and advancement of CRC. The effects of postbiotics, which are bioactive metabolites made by gut bacteria, on inflammation, oxidative stress, and the dynamics of the tumour microenvironment are covered in detail in later chapters. The therapeutic potential of microbiota-targeted approaches, such as probiotics, prebiotics, postbiotics, and faecal microbiota transplantation, is rigorously evaluated.

This book primarily concentrates on the emerging domain of microbiome-based precision medicine, which seeks to individualise colorectal cancer treatment using microbiota-focused diagnostics and therapies. This work emphasises the transformative potential of gut microbiota manipulation in colorectal cancer therapy by integrating advanced research with clinical views.

We express our profound appreciation to our colleagues, mentors, and contributors for their vital insights, and to our families for their steadfast support. Gratitude is extended to the editorial staff at Springer Nature, Humana Press for enabling this

undertaking. We anticipate this book will be a significant resource for researchers, doctors, and healthcare professionals dedicated to enhancing microbiome-based approaches in oncology.

Gwalior, Madhya Pradesh, India
Jabalpur, Madhya Pradesh, India
Uluberia, West Bengal, India

Neeraj Mishra
Ashish Garg
Sumel Ashique

Acknowledgements

Acknowledgement by Dr. Neeraj Mishra

I would also like to express my sincere gratitude to Honourable Founder-President Dr. Ashok K. Chauhan, Ritnand Balved Education Foundation (RBEF) and Dr. Aseem Chauhan, Chancellor, Amity University, Madhya Pradesh. I am thankful to my Honourable Pro-Chancellor Lt. Gen. V. K. Sharma, AVSM (Retd.), Amity University, Gwalior, Madhya Pradesh, India, Vice Chancellor, Prof. R.S. Tomar, Amity University, Gwalior, Madhya Pradesh, Pro-Vice Chancellor (Research) Prof. (Dr.) M. P. Kaushik, Amity University, Gwalior, Madhya Pradesh, India, for his continuous encouragement. Finally, I would like to express my wholehearted appreciation to the faculty and staff members of Amity Institute of Pharmacy, Amity University, Gwalior, Madhya Pradesh.

Acknowledgement Dr. Ashish Garg

I would like to express my deepest gratitude to Dr. Gopal Rai (Principal, Guru Ramdas Khalsa Institute of Science and Technology (GRKIST)-Pharmacy) for his invaluable guidance, encouragement, and unwavering support throughout this journey. I extend my heartfelt appreciation to Sardar K. S. Bansal (President, GGESS) and Sardar J. S. Saini (Secretary, GGESS) for their continuous encouragement and for fostering an environment that nurtures academic excellence and research innovation. Their leadership and vision have been a constant source of inspiration. Lastly, my deepest and most heartfelt gratitude goes to my beloved family, whose unwavering love, patience, and encouragement have been my greatest source of strength.

Contents

1 Gut Microbiota: Role in Health and Disease	1
Msoumeh Bagheri, Azadeh Zahmatkesh, Abrar Hussain, Tahreen Taj, Sumel Ashique, and Naheed Mojtani	
2 Introduction to Gut Microbiota and Its Role in Health and Diseases	15
Somya Sharma, Md Sadique Hussain, Yumna Khan, and Mudasir Maqbool	
3 Molecular Mechanisms of Postbiotics in Colorectal Cancer	47
Sanjesh Kumar, Vijay Singh, Safiya Bee, Syed Mustafizur Rahaman, Komal Kriti, Rekha Shivaram, Mohammad Muztaba, Shreyasi Katari, and Sumel Ashique	
4 Postbiotics and Metabolic Signaling in Colorectal Cancer	83
Rizwan Ahamad, Ubaidulla Uthumansha, Saistha Anjum, Zuber Khan, Sandhyarani Sagavkar, Sandipan Dash, Tahreen Taj, Sanjesh Kumar, Mirazuddin Mollick, and Sumel Ashique	
5 Gut Microbiota and Colorectal Cancer Pathogenesis	99
Anas Islam, Badruddeen, Mohammad Irfan Khan, Mohsin Vahid Khan, and Yusuf Asad	
6 Gut Microbiota in Colorectal Cancer: Fundamentals, Analytical Techniques, and Its Limitations	125
Amit Anand, Antula Kumari, Santhepete Nanjundiah Manjula, and Kenganora Mruthunjaya	
7 Postbiotics: Bioactive Compounds and Their Effects	155
Ashish Garg, Fulden Ulucan-Karnak, Abhavya Shukla, Sweta Garg, Prakash Pandey, Vishal Singh, and Gopal Rai	

8	Impact of Diet, Microbiota, and Postbiotics in Colorectal Cancer (CRC) Management	177
	Ayush Madan, Priya Chaudhary, Dipali Saxena, Mohammad Muztaba, Minesh Patel, Imran Ataurrahman Sheikh, Mohd Tanveer Khan, Touseef Begum, and Sumel Ashique	
9	The Interplay Between Modulation Strategies of Gut Microbiota and Colorectal Cancer Development	197
	Swarupananda Mukherjee, Dipanjan Karati, Priyanka Gupta, Akash Garg, Dipali Saxena, Anas Islam, Parameswari Prabhu, Syed Iqra Naznin, and Sumel Ashique	
10	The Interplay Between Postbiotics and Colorectal Cancer	221
	Kondapuram Parameshwar, C. K. Ashok Kumar, S. Mohanalakshmi, Neha Pathak, and Mohini Kalra	
11	Postbiotics and Colorectal Cancer: Current Research and Clinical Insights	241
	Arifa Mehreen, Afsheen Mansoor, Emaan Mansoor, Hafiz Aamir Ali Kharl, and Shakira Ghazanfar	
12	Gut-Brain Axis and Colorectal Cancer: Neuroimmune Interactions	257
	Akanksha Prasad, Shree Acharya, Amrita Singh, Utsav Raj, and Anuradha Sharma	
13	Gut Microbiota, Postbiotics, and Personalized Medicine in CRC	285
	Ashish Garg and Vijay Sagar Madamsetty	
14	Therapeutic Strategies of Targeting Gut Microbiota in Colorectal Cancer Management	323
	Aniruddha Sen, Pooja S. Murkute, Riya Dave, Md. Abubakar, Sijo Pattam, Satendra Kumar, Neeraj Mishra, Sanjay Dey, and Sumel Ashique	
15	Integrating Probiotics, Postbiotics, and Nanotechnology for Enhanced Treatment Efficacy in Colorectal Cancer	345
	Trideep Saikia, Lima Patowary, Prativa Sadhu, and Damiki Laloo	
16	Postbiotics, Gut Microbiota, and Colorectal Cancer: Implications for Immunotherapy	375
	Maya Magdy Abdelwahab, Mustafa H. Shahin, Yehuda Tri Nugroho Supranoto, Ahmed Hossam Gamil, and Ahmad S. Ghattas	

17 Microbiota-Targeted Therapies for Colorectal Cancer: Current Challenges and Future Directions	399
Harshita Sadhana, Karne Aishwarya Santosh, Paul Gajanan Balaji, and Awesh Kumar Yadav	
18 Diagnostic Approaches for Colorectal Cancer: Gut Microbiota–Based Biomarkers for Colorectal Cancer Detection and Monitoring	429
K. Sandhanam, Bedanta Bhattacharjee, M. Sumithra, Ram Kumar Sahu, and Jiyauddin Khan	
19 Beyond Treatment: Integrating Gut Microbiota and Postbiotic Survivorship and Long-Term Management of Colorectal Cancer	451
Suparna Garai, Ashish Garg, and Amalesh Samanta	
20 Future Perspectives: Advancements in Postbiotics and Gut Microbiota Research and Potential Therapeutic Breakthroughs	467
Priyanka Ray, Tahreen Taj, Sneha De, Richa Dhingra, Tinku Kumar, Sanjay Dey, Swarupananda Mukherjee, Biplab Debnath, Sumel Ashique, and Slim Smaoui	
Index	489


Gut Microbiota and Colorectal Cancer Pathogenesis

Chapter | First Online: 02 July 2025

pp 99–123 | [Cite this chapter](#)

Anas Islam, Badruddeen, Mohammad Irfan Khan, Mohsin Wahid Khan & Yusuf Asad 

 Part of the book series: [Cancer Drug Discovery and Development](#) ((CDD&D))

 22 Accesses

Abstract

This chapter explores the complex relationship between the gut microbiota and the pathogenesis of colorectal cancer (CRC), highlighting the role of microbial dysbiosis in promoting inflammation, DNA damage, and immune dysregulation. It reviews key pro-carcinogenic bacteria, such as *Fusobacterium nucleatum*, *Bacteroides fragilis*, and pks+ *Escherichia coli*, which contribute to tumor initiation and progression. The chapter also discusses the protective effects of beneficial microbes like *Lactobacillus* and *Bifidobacterium*, which help maintain gut health and inhibit carcinogenesis. Therapeutic strategies aimed at modulating the gut microbiota, including dietary interventions, probiotics, prebiotics, fecal microbiota transplantation (FMT), and postbiotics, are examined for their potential in CRC prevention and treatment. Finally, future directions in personalized microbiome-based therapies, diagnostic biomarkers, and the challenges facing clinical translation of gut microbiota research are addressed. The chapter emphasizes the growing importance of targeting the microbiome in CRC management to enhance prevention, diagnosis, and therapeutic outcomes.